FindTrial
Sign In

Use of hyaluronidase as an additive to bupivaciane to in patient positioning for spinal and epidural procedures

Effective of hyaluronidase as an adjuvant to bupivaciane for ultrasound guided pericapsular nerve group block in patient positioning for central neuraxial blockade: a randomised double-blind study. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/09/073495
Enrollment
73
Registered
2024-09-05
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Injection bupivaciane 0.5% and inj hyaluronidase: inj bupivacaine 0.5 % 20 cc and inj. bupivacaine 0.5 % with inj hyaluronidase 300mg , will be given to the patients undergoing hip surg

Sponsors

Akshat Reddy
Lead Sponsor
ESIC PGIMSR medical college
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: patients willing to give informed consent belonging to ASA I and II, patients of either gender, with their age ranging from 18- 60 years and scheduled for elective surgery of hip fracture under central neuraxial blockade.

Exclusion criteria

Exclusion criteria: patients with bleeding disorder, infection at the block site, patients with contraindications for neuraxial blockade like paraplegia, hemiplegia or motor power less than 5/5 patients with history of allergy to the study drugs

Design outcomes

Primary

MeasureTime frame
ease in patient positioning for central neuraxial blockadeTimepoint: 3 min , 6 min, 9 mins, 12 mins 15 mins.—

Secondary

MeasureTime frame
postoperative pain reliefTimepoint: 30 minutes—

Countries

India

Contacts

Public ContactAkshata Reddy

ESIC-PGIMSR MEDICAL COLLEGE, RAJAJINAGAR , BENGALURU.

gbsumalatha@gmail.com9538301443

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026